Horn Margaret A 4

What Happened

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines (RVMD), reported option exercises and open-market sales. On June 15 and June 17, 2026 she exercised multiple option tranches (acquiring a total of 108,?—see details below) at strikes of $40.74, $29.80 and $26.50, and sold 60,400 shares on 6/15 and 29,600 shares on 6/17 in open-market trades. The two recent sales generated proceeds of approximately $9.67M (6/15) and $4.74M (6/17), ~ $14.41M total. The filing also shows a prior sale on 2025-06-16 of 3,575 shares for ~$558K. Some derivative entries are reported at $0.00 reflecting conversion/settlement of the derivative instruments upon exercise.

Key Details

• Transaction dates & prices:
  • 2026-06-15: Exercised 15,546 shares @ $40.74 (cost $633,344) and 44,854 shares @ $29.80 (cost $1,336,649); sold 60,400 shares @ weighted avg $160.17 (proceeds $9,674,304). Multiple sale prices ranged $160.00–$160.3550 per share (weighted avg reported).
  • 2026-06-17: Exercised 573 @ $40.74 (cost $23,344), 3,302 @ $29.80 (cost $98,400), 25,725 @ $26.50 (cost $681,713); sold 29,600 @ weighted avg $160.12 (proceeds $4,739,679). Multiple sale prices ranged $160.00–$160.48 (weighted avg reported).
  • 2025-06-16: Sold 3,575 @ weighted avg $156.12 (proceeds $558,126). Multiple trade prices ranged $156.1105–$156.8250.
• Sales total (6/15 + 6/17): ~90,000 shares for ~ $14.41M.
• The filing includes corresponding derivative disposition lines reported at $0.00 (reflecting conversion of options/derivatives upon exercise).
• Footnotes of note:
  • F1: Some trades were made pursuant to a 10b5‑1 trading plan adopted March 12, 2026.
  • F4: Some sales were executed under a Rule 10b5‑1 instruction to satisfy tax withholding on RSU vesting.
  • F2/F6: Filing references RSUs (73,050 and 66,201) as part of holdings.
  • F8/F9/F10: Option grants subject to monthly vesting schedules (1/48th per month) from various vesting commencement dates (March 1, 2023/2024/2025).
• Shares owned after the transactions: not specified in the excerpt of the filing provided.
• Filing timeliness: Reported on June 17, 2026 for transactions dated June 15–17, 2026 (no late‑filing flag indicated in provided data).

Context

• These entries show exercised options (transaction code M) followed by open‑market sales (S). When option exercises are immediately followed by market sales, it often reflects a cashless exercise or sales to cover exercise costs and tax withholding; here the filing explicitly notes a 10b5‑1 tax withholding instruction for RSU vesting. No inference should be made about insider sentiment beyond the record of purchases/exercises and sales — the filing is factual reporting of exercises and routine / planned sales.